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Hyperbaric oxygen therapy is a treatment for wounds in any location and of any duration that has been
misunderstood for 353 years. Since 2008 it has been applied to the persistent post-concussion syndrome of mild
traumatic brain injury by civilian and later military researchers with apparent conflicting results. The civilian studies
are positive and the military-funded studies are a mixture of misinterpreted positive data, indeterminate data, and
negative data. This has confused the medical, academic, and lay communities. The source of the confusion is a
fundamental misunderstanding of the definition, principles, and mechanisms of action of hyperbaric oxygen
therapy. This article argues that the traditional definition of hyperbaric oxygen therapy is arbitrary. The article
establishes a scientific definition of hyperbaric oxygen therapy as a wound-healing therapy of combined increased
atmospheric pressure and pressure of oxygen over ambient atmospheric pressure and pressure of oxygen whose main
mechanisms of action are gene-mediated. Hyperbaric oxygen therapy exerts its wound-healing effects by expression
and suppression of thousands of genes. The dominant gene actions are upregulation of trophic and anti-inflammatory
genes and down-regulation of pro-inflammatory and apoptotic genes. The combination of genes affected depends on
the different combinations of total pressure and pressure of oxygen. Understanding that hyperbaric oxygen therapy is
a pressure and oxygen dose-dependent gene therapy allows for reconciliation of the conflicting TBI study results as
outcomes of different doses of pressure and oxygen.
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Confusion over the conflicting conclusions of recent
civilian and United States Department of Defense
(DoD) trials of hyperbaric oxygen therapy (HBOT) in
the treatment of mild traumatic brain injury (mTBI)
persistent post-concussion syndrome (PPCS) [1–6] have
focused attention on critical flaws [7, 8] in the historical
definition of HBOT [9] that beg the question “What is
hyperbaric oxygen therapy?” The answer to this question
has led to a re-appraisal of HBOT as a dual-component
[7, 8] gene therapy [7] that is poised to not only change,
but also expand the field of hyperbaric therapy.Main text
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abs or higher.”) [9] focuses solely on the absolute pressure
of 100 % oxygen above 1.40 ATA. The 1.4 ATA threshold
is both arbitrary and limiting when considering that, by
definition, oxygen at 1.399999 ATA would not be hyper-
baric oxygen therapy. Yet, there is no published data on a
difference in clinical efficacy between 1.40 and 1.399999
ATA oxygen for any diagnosis. Furthermore, any 100 %
oxygen exposure greater than ambient atmospheric pres-
sure or between 1.0 and 1.4 ATA, or total pressurization
between 1.0 and 1.4 ATA of oxygen-enriched breathing
gas > .21 ATA oxygen would not be hyperbaric oxygen
therapy. This excludes a substantial body of clinical lit-
erature [10], especially Russian hyperbaric literature
where pressures between 1.1 and 1.4 ATA were com-
mon (See abstracts of 7th International Congress on
Hyperbaric Medicine, Moscow, 1981). The definition is
also limiting by its exclusion of the acknowledged bio-
activity of pressure [7, 11]. While relevant in studies
where beneficial effects in pressurized air controlistributed under the terms of the Creative Commons Attribution License (http://
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pressure of oxygen [12, 13], it is also relevant to the er-
roneous claim in DoD studies [3–5] that the 2.0 ATA/
normoxic control group is a sham. Both the sham claim
and the historical definition of HBOT are further erro-
neous when considering that every clinical HBOT is a
combination of increasing partial pressure of oxygen
and total pressure during pressurization and for at least
the first 18 min of treatment [14], and decreasing par-
tial pressure of oxygen during decompression.
More accurately, the definition of HBOT is a therapy
of increased total atmospheric pressure and partial pres-
sure of oxygen over ambient total and oxygen partial
pressures [7, 8]. The bioactivity of increased 100 % total
atmospheric pressure oxygen is well known [7–9]. The
bioactivity of increased atmospheric pressure is un-
known to the clinical hyperbaric medicine community,
but well-documented in an extensive basic science litera-
ture [11]. Dozens of investigators have reported wide-
spread biological effects of increased pressure across the
entire phylogenetic spectrum that begin as early as 30 s
after compression [11].
HBOT In the United States is primarily applied to
acute and chronic wound conditions and certain infec-
tions [9]. Infections are wound conditions due to the
effects of the inflammatory reaction and scar formation.
HBOT has a wide range of effects on wound pathophysi-
ology [9]. The daily input of HBOT produces wound
healing. HBOT heals wounds by the trophic processes of
blood vessel, connective tissue, bone, and skin growth
[15–18]. These trophic effects require mitotic activity,
however, the intermediary steps for trophism were a void
in hyperbaric science until 1997 [19].
Siddiqui, et al. [19] proposed that HBOT was a de-
oxyribonucleic acid (DNA) signaling agent based on
wound-healing synergy of oxygen and growth factors
and an HBOT-induced change in the oxygen capaci-
tance of ischemic animal wounds. Multiple studies on
HBOT-generated single gene products followed [20–32].
Recently, gene array analyses have demonstrated wide-
spread gene expression/suppression effects of hyperoxia
and/or increased atmospheric pressure: 1) Cells grown in
2 ATA air (~.40 ATA oxygen) versus cells in 40 % oxy-
gen at 1 ATA expressed cell adhesion, stress response,
transcription, apoptosis, tumor suppressor-related, and
mitogen-activated protein kinase-related genes [33], 2)
Independent and overlapping genes are sensitive to in-
creases in pressure, oxygen, or both [34], 3) As many as
8101 genes were either up- or down-regulated over
24 h after a single exposure to HBOT [35] (upregulated
genes were primarily growth and repair hormone and
the anti-inflammatory genes; downregulated genes were
the pro-inflammatory and apoptotic genes), and 4)
Differential suppression of inflammatory genes at 1.0,1.5, and 2.4 ATA oxygen with maximal suppression at
1.5 ATA [36]. While the oxygen studies’ results are par-
tially qualified by in vitro:in vivo oxygen partial pres-
sure differences [34, 37], the pressure results are not.
The unqualified conclusion is that a substantial number
of human genes are sensitive to increased atmospheric
pressure, hyperoxia at increased atmospheric pressure,
or both.
The lack of appreciation of the dual-component na-
ture of hyperbaric oxygen therapy and the bioactivity of
both pressure and hyperoxia at increased atmospheric
pressure is widespread, but most evident in the recent
DoD trials of HBOT in mTBI PPCS [1–6]. A review in
Medical Gas Research [38] correctly mentions that one
of the DoD studies does “…not address any potential
therapeutic benefit of higher pressures in the absence
of increased oxygen tension,” however, it does not elab-
orate on the literature describing bioactivity of pres-
sure. An earlier review [39] mentions only the oxygen
component of HBOT. A third review [40] noted, “Un-
fortunately, agreement that HBOT has a positive effect
on TBI has not yet been reached due to the difference
in external conditions.” Absent in this review was a dis-
cussion on the different doses of HBOT used in the
various studies and the erroneous assumption in two of
the studies that the “sham” groups were not treatment
groups that used different doses of hyperbaric therapy.
This erroneous assumption is present in all of the DoD
mTBI HBOT PPCS studies [7, 8]. When viewed as
multi-dose studies the results of the DoD studies become
congruent with the results of civilian studies [41–44],
suggesting effectiveness of some doses of hyperbaric
therapy [1, 6, 41–44], ineffectiveness of others [3–5],
and harm of another [2]. This appreciation of dosing
differences raises the question of potential effectiveness
of many other doses of pressure and hyperoxia in mTBI
PPCS. They also spawn a rethinking and re-appraisal of
the disputed historical claims of efficacy of HBOT in
the treatment of well over one hundred diseases [45]
dating to 1662, and the widely differing number of
treatable indications in less scientifically restrictive
countries, e.g. China [46], versus the United States.
Conclusions
In conclusion, HBOT is the use of increased total at-
mospheric pressure and partial pressure of oxygen over
ambient total and oxygen partial pressures to treat vari-
ous disease processes and their diseases. The combin-
ation of increased atmospheric pressure and hyperoxia
express or suppress upto 8101 genes in human cells
[35]. Hyperbaric oxygen therapy appears to be the old-
est, most enduring, and most effective gene therapy.
Physicians and researchers are playing a symphony with
gene expression and suppression, the combination of
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partial pressures of oxygen. It is apparent that dosing of
hyperbaric therapy is in its infancy, particularly in the
pressure ranges from 1–2 ATA and across the spectrum
of unexplored fractional inspired oxygen concentrations
at pressures ≥ 1 ATA. It is also apparent that multiple
doses of hyperbaric therapy are effective in the treat-
ment of PPCS while others are not. With an appreci-
ation of the scientific definition of hyperbaric oxygen
therapy the field of Undersea and Hyperbaric Medicine
is poised to rapidly expand with investigation of the
lower dosing ranges of pressure and hyperoxia for a
multitude of diagnoses.
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